Abstract CT239: IMpower010: Updated overall survival and safety results from Asian patients in a Phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA NSCLC
Year: 2024
Type: conference-abstract
Source: Cancer Research
Institutions: Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences, Zhejiang Cancer Hospital, Peking University Cancer Hospital, First Affiliated Hospital of Guangzhou Medical University, First Hospital of China Medical University, China Medical University, First Affiliated Hospital of Soochow University, NewYork–Presbyterian Hospital, Weill Cornell Medicine, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Stanford Medicine, Stanford Cancer Institute, Stanford University, Roche (Switzerland), Roche (United Kingdom), Genentech, Annexon Biosciences (United States), Instacart (United States), Tongji University, Shanghai Pulmonary Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4393987596